|
1
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Machlowska J, Baj J, Sitarz M, Maciejewski
R and Sitarz R: Gastric cancer: Epidemiology, risk factors,
classification, genomic characteristics and treatment strategies.
Int J Mol Sci. 21:40122020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thrift AP and El-Serag HB: Burden of
gastric cancer. Clin Gastroenterol Hepatol. 18:534–542. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
VanOpstall C, Perike S, Brechka H, Gillard
M, Lamperis S, Zhu B, Brown R, Bhanvadia R and Griend DJV:
MEIS-mediated suppression of human prostate cancer growth and
metastasis through HOXB13-dependent regulation of proteoglycans.
Elife. 9:e536002020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie B, Bai B, Xu Y, Liu Y, Lv Y, Gao X, Wu
F, Fang Z, Lou Y, Pan H and Han W: Tumor-suppressive function and
mechanism of HOXB13 in right-sided colon cancer. Signal Transduct
Target Ther. 4:512019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang X, Wang R, Wu Z and Bai P: Circular
RNA ITCH suppressed prostate cancer progression by increasing
HOXB13 expression via spongy miR-17-5p. Cancer Cell Int.
19:3282019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Okuda H, Toyota M, Ishida W, Furihata M,
Tsuchiya M, Kamada M, Tokino T and Shuin T: Epigenetic inactivation
of the candidate tumor suppressor gene HOXB13 in human renal cell
carcinoma. Oncogene. 25:1733–1742. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sui BQ, Zhang CD, Liu JC, Wang L and Dai
DQ: HOXB13 expression and promoter methylation as a candidate
biomarker in gastric cancer. Oncol Lett. 15:8833–8840.
2018.PubMed/NCBI
|
|
9
|
Guo C, Chu H, Gong Z, Zhang B, Li C, Chen
J and Huang L: HOXB13 promotes gastric cancer cell migration and
invasion via IGF-1R upregulation and subsequent activation of
PI3K/AKT/mTOR signaling pathway. Life Sci. 278:1195222021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Y, Huang T, Zhang J, Wong CC, Zhang
B, Dong Y, Wu F, Tong JHM, Wu WKK, Cheng ASL, et al: TEAD1/4 exerts
oncogenic role and is negatively regulated by miR-4269 in gastric
tumorigenesis. Oncogene. 36:6518–6530. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han Y: Analysis of the role of the Hippo
pathway in cancer. J Transl Med. 17:1162019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiao S, Wang H, Shi Z, Dong A, Zhang W,
Song X, He F, Wang Y, Zhang Z, Wang W, et al: A peptide mimicking
VGLL4 function acts as a YAP antagonist therapy against gastric
cancer. Cancer Cell. 25:166–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Machlowska J, Maciejewski R and Sitarz R:
The pattern of signatures in gastric cancer prognosis. Int J Mol
Sci. 19:16582018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Q, Tian S, Liu ZR and Dong WG:
Knockdown of RIPK2 inhibits proliferation and migration, and
induces apoptosis via the NF-k B signaling pathway in gastric
cancer. Front Genet. 12:6274642021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng MM, Li BX, Yang L and Guan QL: CBX2
depletion inhibits the proliferation, invasion and migration of
gastric cancer cells by inactivating the YAP/β-catenin pathway. Mol
Med Rep. 23:1372021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cannon-Albright LA, Stevens J, Teerlink CC
and Agarwal N: The HOXB13 p.Gly84Glu variant observed in an
extended five generation high-risk prostate cancer pedigree
supports risk association for multiple cancer sites. Cancer
Epidemiol. 69:1018342020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Sun Y, Xu TY, Qian K, Huang B,
Zhang K, Song Z, Qian T, Shi J and Li L: HOXB13 promotes
proliferation, migration, and invasion of glioblastoma through
transcriptional upregulation of lncRNA HOXC-AS3. J Cell Biochem.
120:15527–15537. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lim B, Kim HJ, Heo H, Huh N, Baek SJ, Kim
JH, Bae DH, Seo EH, Lee SI, Song KS, et al: Epigenetic silencing of
miR-1271 enhances MEK1 and TEAD4 expression in gastric cancer.
Cancer Med. 7:3411–3424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shuai Y, Ma Z, Liu W, Yu T, Yan C, Jiang
H, Tian S, Xu T and Shu Y: TEAD4 modulated LncRNA MNX1-AS1
contributes to gastric cancer progression partly through
suppressing BTG2 and activating BCL2. Mol Cancer. 19:62020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fagerberg L, Hallstrom BM, Oksvold P,
Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S,
Danielsson A, Edlund K, et al: Analysis of the human
tissue-specific expression by genome-wide integration of
transcriptomics and antibody-based proteomics. Mol Cell Proteomics.
13:397–406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang WJ, Gao YJ, Li PX, Shi Z, Guo T, Li
F, Han X, Feng Y, Zheng C, Wang Z, et al: VGLL4 functions as a new
tumor suppressor in lung cancer by negatively regulating the
YAP-TEAD transcriptional complex. Cell Res. 24:331–343. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y, Shen H, Withers H, Yang N, Denson
KE, Mussell AL, Truskinovsky A, Fan Q, Gelman IH, Frangou C and
Zhang J: VGLL4 selectively represses YAP-dependent gene induction
and tumorigenic phenotypes in breast cancer. Sci Rep. 7:61902017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiao S, Li C, Hao Q, Miao H, Zhang L, Li L
and Zhou Z: VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt
and Hippo signalling in colorectal cancer. Nat Commun. 8:140582017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li H, Wang Z, Zhang W, Qian K, Liao G, Xu
W and Zhang S: VGLL4 inhibits EMT in part through suppressing
Wnt/β-catenin signaling pathway in gastric cancer. Med Oncol.
32:832015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sugihara T, Isomoto H, Gores G and Smoot
R: YAP and the Hippo pathway in cholangiocarcinoma. J
Gastroenterol. 54:485–491. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stanger BZ: Quit your YAPing: A new target
for cancer therapy. Genes Dev. 26:1263–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
